- Home
- BEPC vs LEGN Comparison
BEPC vs LEGN Comparison
Compare BEPC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEPC
- LEGN
- Stock Information
- Founded
- BEPC 2019
- LEGN 2014
- Country
- BEPC United States
- LEGN United States
- Employees
- BEPC N/A
- LEGN N/A
- Industry
- BEPC Electric Utilities: Central
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- BEPC Utilities
- LEGN Health Care
- Exchange
- BEPC Nasdaq
- LEGN Nasdaq
- Market Cap
- BEPC 6.1B
- LEGN 5.4B
- IPO Year
- BEPC N/A
- LEGN 2020
- Fundamental
- Price
- BEPC $33.18
- LEGN $36.08
- Analyst Decision
- BEPC Buy
- LEGN Strong Buy
- Analyst Count
- BEPC 4
- LEGN 12
- Target Price
- BEPC $35.00
- LEGN $73.36
- AVG Volume (30 Days)
- BEPC 767.5K
- LEGN 1.0M
- Earning Date
- BEPC 11-07-2025
- LEGN 08-11-2025
- Dividend Yield
- BEPC 4.49%
- LEGN N/A
- EPS Growth
- BEPC N/A
- LEGN N/A
- EPS
- BEPC N/A
- LEGN N/A
- Revenue
- BEPC $3,882,000,000.00
- LEGN $796,838,000.00
- Revenue This Year
- BEPC $62.68
- LEGN $70.75
- Revenue Next Year
- BEPC $8.90
- LEGN $52.47
- P/E Ratio
- BEPC N/A
- LEGN N/A
- Revenue Growth
- BEPC N/A
- LEGN 74.75
- 52 Week Low
- BEPC $23.73
- LEGN $27.34
- 52 Week High
- BEPC $37.00
- LEGN $57.54
- Technical
- Relative Strength Index (RSI)
- BEPC 44.66
- LEGN 48.36
- Support Level
- BEPC $32.76
- LEGN $34.14
- Resistance Level
- BEPC $34.70
- LEGN $36.17
- Average True Range (ATR)
- BEPC 0.64
- LEGN 1.08
- MACD
- BEPC -0.05
- LEGN 0.07
- Stochastic Oscillator
- BEPC 21.65
- LEGN 48.67
About BEPC Brookfield Renewable Corporation
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia, and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners LP and Brookfield Renewable Corp.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.